Plazma pTau181 ve amiloid belirteçleri idiyopatik REM uyku davranış bozukluğunda demansa dönüşümü öngörmektedir.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Blood-based biomarkers for Alzheimer's disease (AD) pathology have been investigated intensively as markers for AD-related neurodegeneration. Comorbid AD pathology is common in dementia with Lewy bodies (DLB). Accordingly, we hypothesized that plasma biomarkers associated with AD pathology might be useful to predict DLB in a cohort of idiopathic/isolated REM sleep behaviour disorder (iRBD), an incipient synucleinopathy. The aim of this study was to determine whether plasma amyloid-β and pTau181 biomarkers can predict DLB. This longitudinal single-centre (Canada) cohort study included 158 individuals with polysomnography-confirmed iRBD between September 2004 and October 2022, each providing blood plasma samples, who were then offered prospective follow-up. Plasma Aβ40, Aβ42 and pTau181 levels were measured using NeuroToolKit, a prototype assay panel of neurodegeneration (Roche Diagnostics International Ltd). The primary outcome was the association between plasma biomarkers at baseline and eventual development of DLB. Correlations between plasma markers and baseline cognitive tests were assessed. A total of 142 iRBD participants [109 male (77%); mean ± SD, 67.6 ± 8.0 years of age] were included in the final analysis. On prospective follow-up (2.9 ± 2.1 years after sampling), 32 individuals phenoconverted to a defined neurodegenerative syndrome (18 DLB, 13 Parkinson's disease and one multiple system atrophy). The combined phenoconvertor group had lower baseline plasma Aβ42/40 ratio compared with non-phenoconvertors (mean ± SD, 0.103 ± 0.010 versus 0.114 ± 0.012, P < 0.001) and higher pTau181 levels (0.993 ± 0.354 versus 0.784 ± 0.266 pg/ml, P = 0.008). When divided by phenoconversion subtype, significant differences were seen selectively in DLB convertors [Aβ42/40 = 0.101 ± 0.010, difference -0.011, 95% confidence interval (-0.016; -0.005), P < 0.001; pTau181 = 1.144 ± 0.326 pg/ml, difference 0.282 pg/ml, 95% confidence interval (0.146; 0.418), P < 0.001]. Cross-sectional analysis showed that plasma pTau181 (but not Aβ42/40) was correlated with cognitive tests across various domains. Our results indicate that plasma Aβ42/40 ratio and pTau181 can predict conversion to DLB in iRBD.

İlgili konular